PR Newswire BiotechOriginal article
T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer
Phase 2approvedMT027Positive
AI Analysis
Summary
T-MAXIMUM PHARMACEUTICAL received FDA clearance to initiate a Phase 2 clinical study of MT027, a B7-H3-targeted allogeneic CAR-T therapy, in patients with brain metastases from lung and breast cancer.
Clinical Trial Data
Phase
Phase 2
Outcome Details
FDA clearance to initiate Phase 2 clinical study
Importance:7/10
Sentiment:
0.80
CAR-TallogeneicB7-H3FDA clearancebrain metastasesimmuno-oncology
Read the original article
Published by PR Newswire Biotech on October 12, 2026 10:50 AM